Safety and Activity of Docetaxel and Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer-Reference-Cited by-同舟云学术

Safety and Activity of Docetaxel and Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer

Published:2003-02 Issue:1 Volume:26 Page:95-97
ISSN:0277-3732
Container-title:American Journal of Clinical Oncology
language:en
Short-container-title:American Journal of Clinical Oncology

Author:

Montemurro Filippo,Choa Gabriella,Faggiuolo Roberto,Sperti Elisa,Capaldi Antonio,Donadio Michela,Minischetti Monica,Salomone Attilio,Vietti-Ramus Guido,Alabiso Oscar,Aglietta Massimo

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference8 articles.

1. Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene

2. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

3. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

4. Docetaxel and Herceptin: Foundation for Future Strategies

5. Reporting results of cancer treatment

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study;Future Oncology;2014-04

2. A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer;Annals of Oncology;2013-07

3. HER2-positive breast cancer: trastuzumab, lapatinib and emerging therapies;Drug Discovery Today: Therapeutic Strategies;2012-09

4. Methods for investigation of targeted kinase inhibitor therapy using chemical proteomics and phosphorylation profiling;Biochemical Pharmacology;2010-09

5. Clinical Efficacy of Taxane–Trastuzumab Combination Regimens for HER-2–Positive Metastatic Breast Cancer;The Oncologist;2008-05-01